当前位置: X-MOL 学术Eur. Heart J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
European Heart Journal ( IF 37.6 ) Pub Date : 2017-07-27 , DOI: 10.1093/eurheartj/ehx355
Denise Hilfiker-Kleiner 1 , Arash Haghikia 1, 2 , Dominik Berliner 1 , Jens Vogel-Claussen 3 , Johannes Schwab 4 , Annegret Franke 5 , Marziel Schwarzkopf 5 , Philipp Ehlermann 6 , Roman Pfister 7 , Guido Michels 7 , Ralf Westenfeld 8 , Verena Stangl 9 , Ingrid Kindermann 10 , Uwe Kühl 2 , Christiane E. Angermann 11 , Axel Schlitt 12 , Dieter Fischer 1 , Edith Podewski 1 , Michael Böhm 10 , Karen Sliwa 13 , Johann Bauersachs 1
Affiliation  

An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM.

中文翻译:

溴隐亭治疗围产期心肌病:一项多中心随机研究

抗血管生成分裂的催乳素片段被认为是围产期心肌病(PPCM)的原因。实验和首次临床观察表明,催乳激素释放抑制剂溴隐亭在PPCM中具有有益作用。
更新日期:2017-09-18
down
wechat
bug